Carmen Criscitiello, MD, PhD

home / authors / carmen-criscitiello-md-phd

Articles

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ;Carmen Criscitiello, MD, PhD;Giuseppe Curigliano, MD, PhD;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

December 13th 2021

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Optimizing Therapy in HER2+ MBC Across the Globe

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ;Giuseppe Curigliano, MD, PhD;Carmen Criscitiello, MD, PhD;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

December 13th 2021

A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.

Updates in the Management of HER2+ MBC With Brain Metastases

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Carmen Criscitiello, MD, PhD

December 6th 2021

Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.

Novel Combination Approaches for HER2+ MBC

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ;Carmen Criscitiello, MD, PhD

November 29th 2021

An overview of novel combination regimens being investigated for the treatment of HER2+ metastatic breast cancer.

T-DXd for HER2+ MBC and Interstitial Lung Disease

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ;Carmen Criscitiello, MD, PhD

November 22nd 2021

Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.

Managing TRAEs Associated With Novel HER2+ MBC Therapies

Giuseppe Curigliano, MD, PhD;Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ;Tiffany A. Traina, MD;Carmen Criscitiello, MD, PhD

November 22nd 2021

Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.

Updated Data From DESTINY-Breast03 in HER2+ MBC

Giuseppe Curigliano, MD, PhD;Carmen Criscitiello, MD, PhD

November 15th 2021

Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.

Global Trends in HER2+ MBC

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ;Carmen Criscitiello, MD, PhD;Giuseppe Curigliano, MD, PhD;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

November 8th 2021

Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.